Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nervgen Pharma Corp (NGENF)

Nervgen Pharma Corp (NGENF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NGENF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4000 +9.29%
on 04/18/24
1.7700 -13.56%
on 05/06/24
-0.0800 (-4.97%)
since 04/10/24
3-Month
1.4000 +9.29%
on 04/18/24
2.7400 -44.16%
on 02/29/24
-1.1500 (-42.91%)
since 02/09/24
52-Week
1.1500 +33.04%
on 05/16/23
2.9900 -48.83%
on 02/08/24
+0.3400 (+28.57%)
since 05/10/23

Most Recent Stories

More News
NervGen Files Management Information Circular and Announces Board of Directors Transition

Bill Radvak to transition to Board Advisor following decision to not stand for re-election to NervGen's Board of DirectorsAnnual General Meeting of Shareholders to be held on June 4, 2024Vancouver, British...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Engages Russo Partners LLC to Provide Public Relations Services

Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates

Anticipated completion of enrollment of the chronic cohort in the Phase 1b/2a clinical trial in Q2 2024CA$23 million bought deal financing completed in March 2024 provides expected cash runway through...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company

Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Grants Stock Options

Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

On track to complete enrollment of the chronic cohort in Q2 2024Data readout from chronic cohort expected in Q3 2024Planning underway to make NVG-291 available to placebo-treated subjects following cohort...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates

Phase 1a/2b clinical trial of NVG-291 underway with dosing of individuals with spinal cord injury; results from chronic cohort expected in mid-2024 Fast Track designation granted by U.S. Food and Drug...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki

Dr. Silver's life work, culminating in NervGen's NVG-291, is currently in a Phase 1b/2a clinical trial for individuals with spinal cord injury.Vancouver, British Columbia--(Newsfile Corp. - November 8,...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Designation Facilitates and Expedites Development of Drugs for Patients with Serious Unmet Medical Needs Enrollment Progressing in NVG-291 Phase 1b/2a Clinical Trial, with Initial Cohort Data Expected...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)
NervGen Pharma Appoints John Ruffolo to Board of Directors

Extensive experience in private equity, venture capital and advising high growth, innovative companiesBrings personal experience and knowledge of spinal cord injury to NervGen's board Important board addition...

NGENF : 1.5300 (+2.27%)
NGEN.VN : 2.070 (+2.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Key Turning Points

3rd Resistance Point 1.6000
2nd Resistance Point 1.5700
1st Resistance Point 1.5500
Last Price 1.5300
1st Support Level 1.5000
2nd Support Level 1.4700
3rd Support Level 1.4500

See More

52-Week High 2.9900
Fibonacci 61.8% 2.2871
Fibonacci 50% 2.0700
Fibonacci 38.2% 1.8529
Last Price 1.5300
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar